HEPHL1

Across TCGA pan-cancer cohorts, HEPHL1 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated HEPHL1 data layer compared with 26 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine carcinosarcoma (UCS), where higher HEPHL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated HEPHL1 expression acts as an unfavorable survival marker.

UCS, BLCA, and HNSC are the cancer types where HEPHL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCS	DFS	Median	IV	0.132	0.718	.002	24	view →
BLCA	OS	Median	All	0.069	0.688	<.001	18	view →
HNSC	DFS	Median	II,III,IV	0.101	0.695	<.001	15	view →
COAD	OS	Median	III,IV	0.163	0.791	.004	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	9	view →
PRAD	DFS	Median	All	0.617	0.886	.041	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	OS	Median	All	0.690	0.838	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

HEPHL1–UCS (DFS)

Open the UCS breakdown →